Arctic Bioscience AS (ABS.OL)
- Previous Close
3.8500 - Open
4.1000 - Bid 3.6000 x --
- Ask 3.6400 x --
- Day's Range
3.6000 - 4.1100 - 52 Week Range
1.6500 - 16.8000 - Volume
56,442 - Avg. Volume
96,159 - Market Cap (intraday)
97.149M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand worldwide. The company was incorporated in 2011 and is headquartered in Ørsta, Norway.
www.arctic-bioscience.comRecent News: ABS.OL
View MorePerformance Overview: ABS.OL
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABS.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABS.OL
View MoreValuation Measures
Market Cap
102.75M
Enterprise Value
84.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.11
Price/Book (mrq)
0.44
Enterprise Value/Revenue
2.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-107.95%
Return on Assets (ttm)
-10.30%
Return on Equity (ttm)
-20.43%
Revenue (ttm)
44.4M
Net Income Avi to Common (ttm)
-47.93M
Diluted EPS (ttm)
-1.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.28M
Total Debt/Equity (mrq)
10.30%
Levered Free Cash Flow (ttm)
-70.9M